OSE Immunotherapeutics SA (0RAD.L)

6.86 +6.86 (+9.77%) At close: 09:32AM GMT

OSE Immunotherapeutics SA

22, boulevard Benoni Goullin
Nantes 44200
France
33 2 28 29 10 10
https://www.ose-immuno.com

Sector(s): 
Industry: 
Full-time employees: 60

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Dominique Costantini M.D.	Founder, Chairman & Director of Devel.	407.92k	N/A	1955
Dr. Nicolas Poirier Ph.D.	CEO, Chief Scientific Officer & Director	17.81k	N/A	1982
Mr. Alexis Peyroles	Consultant	586.59k	N/A	1974
Ms. Anne-Laure Autret-Cornet	Chief Financial Officer	N/A	N/A	N/A
Dr. Alain Chatelin M.D.	Medical Director	N/A	N/A	N/A
Dr. Jean-Pascal Conduzorgues Pharm.D.	Chief Manufacturing Officer & Qualified Person (QP)	N/A	N/A	N/A
Bérangère Vasseur	Chief Medical Officer Immuno-Oncology	N/A	N/A	N/A
Mr. Julien Perrier	Chief Commercial Officer	N/A	N/A	N/A
Ms. Linda Lebon M.Sc.	Chief Regulatory Officer	N/A	N/A	1967
Dr. Silvia Comis M.D.	Head of Clinical Devel.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

Corporate governance

OSE Immunotherapeutics SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.